- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06816524
The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency
The Effects of Iron Treatment on Malaria, Typhoid and Measles Vaccine Response in Kenyan Infants With Iron Deficiency: A Randomized Controlled Trial
Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination.
In this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21/Matrix-M, Typhim VI and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Nicole Stoffel, PhD
- Telefonnummer: +41 044 632 83 93
- E-post: nicole.stoffel@hest.ethz.ch
Studer Kontakt Backup
- Navn: Lara Del Curto, MSc
- Telefonnummer: +41 0774212070
- E-post: lara.delcurto@pharma.ethz.ch
Studiesteder
-
-
Kwale County
-
Msambweni, Kwale County, Kenya, 80404
- Rekruttering
- Msambweni District Hospital
-
Ta kontakt med:
- Edith Mwasi, MD
- E-post: edithmwasi@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Subject's caregiver is willing and able to give informed consent
- Male or Female, 6 months (+/- 2 weeks) of age
- Mother ≥15 years of age
- Iron deficient (erythrocyte zinc protoporphyrin (ZnPP) >61 μmol/mol heme) or anemic (hemoglobin (Hb) <105 g/L)
Exclusion Criteria:
- Severely anemic (Hb <70 g/L)
- Hemoglobinopathies HbCC, HbSC, or HbSS
- Malaria, Measles or Typhoid vaccination prior to enrollment
- Medical condition that precludes study involvement
- Iron supplementation 2 weeks before enrollment
- Acute or chronic infection (e.g. HIV)
- Wasted (length for height z score of ≥-2) or underweight (weight for age z score ≥-2).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Iron treatment group
daily multivitamin + daily iron syrup from age 6 to 10 months |
Iron syrup administered daily from 6 to 10 months of age. Multivitamin syrup administered daily from 6 to 10 months of age. R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age. Measles-Rubella vaccine administered at 9 months of age. |
|
Annen: Control group
daily multivitamin syrup from age 6 to 10 months |
Multivitamin syrup administered daily from 6 to 10 months of age. R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age. Measles-Rubella vaccine administered at 9 months of age. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
NANP-specific IgG
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG antibodies targeting the NANP repeat region of the circumsporozoite protein (CSP) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Anti-measles IgG
Tidsramme: At 10 months of age (1 month after MR vaccine administration)
|
IgG antibodies targeting measles antigen |
At 10 months of age (1 month after MR vaccine administration)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Anti-typhoid IgG
Tidsramme: At 10 months of age (1 month after Typhim VI administration)
|
IgG antibodies targeting typhoid antigen |
At 10 months of age (1 month after Typhim VI administration)
|
|
C-terminal-specific IgG
Tidsramme: At 10 months of age (1 month after 3rd R21/Matrix-M dose)
|
IgG antibodies targeting the C-terminal region of CSP |
At 10 months of age (1 month after 3rd R21/Matrix-M dose)
|
|
C-terminal-specific IgG
Tidsramme: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
IgG antibodies targeting the C-terminal region of CSP |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
C-terminal-specific IgG
Tidsramme: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
IgG antibodies targeting the C-terminal region of CSP |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
|
NANP-specific IgG
Tidsramme: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
IgG antibodies targeting the NANP repeat region of CSP |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
NANP-specific IgG
Tidsramme: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
IgG antibodies targeting the NANP repeat region of CSP |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
|
Full-length CSP-specific IgG
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG antibodies targeting the full-length CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgM
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgM antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgA
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgA antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG4
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG4 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG3
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG3 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG2
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG2 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG1
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG1 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
IgG avidity to measles antigen
Tidsramme: At 10 months of age (1 month after MR vaccine administration)
|
Avidity index for IgG binding to measles antigen |
At 10 months of age (1 month after MR vaccine administration)
|
|
IgG avidity to typhoid antigen
Tidsramme: At 10 months of age (1 month after Typhim VI administration)
|
Avidity index for IgG binding to typhoid antigen |
At 10 months of age (1 month after Typhim VI administration)
|
|
IgG avidity to NANP-specific CSP
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Avidity index for IgG binding to NANP CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
IgG avidity to C-terminal CSP
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Avidity index for IgG binding to C-terminal CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Full-length CSP-specific IgG seropositivity
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
C-terminal-specific IgG seropositivity
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
C-terminal-specific IgG seropositivity
Tidsramme: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
C-terminal-specific IgG seropositivity
Tidsramme: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
|
NANP-specific IgG seropositivity
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG seropositivity
Tidsramme: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
NANP-specific IgG seropositivity
Tidsramme: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Inhibition of Plasmodium falciparum sporozoite-invasion of HC-04 hepatic cells
Tidsramme: At 10 months of age (1 months after the 3rd R21/Matrix-M dose)
|
Exploratory in vitro assay on IgG functionality in lowest and highest responders |
At 10 months of age (1 months after the 3rd R21/Matrix-M dose)
|
|
Opsonic phagocytosis of CSP-coated beads by THP-1 cells
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Exploratory in vitro assay of IgG opsonization functionality in lowest and highest responders |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells
Tidsramme: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Exploratory in vitro assay performed in lowest and highest responders |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Antibody levels against a panel of antigens associated with malaria exposure in the previous year
Tidsramme: At 7 months of age (baseline)
|
Exploratory in all participants |
At 7 months of age (baseline)
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Nicole Stoffel, PhD, ETH Zurich
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Vektorbårne sykdommer
- Myggbårne sykdommer
- Metabolske sykdommer
- Infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Protozoiske infeksjoner
- Parasittiske sykdommer
- Forstyrrelser i jernmetabolisme
- Paramyxoviridae-infeksjoner
- Mononegavirales-infeksjoner
- Morbillivirus infeksjoner
- Ernæringsmessige og metabolske sykdommer
- Jernmangel
- Malaria
- Meslinger
- Biologiske produkter
- Komplekse blandinger
- Vaksiner
- Protozoavaksiner
- Malariavaksiner
Andre studie-ID-numre
- MEMA
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .